Bicycle Therapeutics plc: Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% (including one complete response) and 67%, respectively

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,United States ,David Borah ,Dominic Smethurst ,Sarah Sutton ,Kevin Lee ,Exchange Commission ,Nasdaq ,Chief Medical Officer ,Bicycle Toxin Conjugate ,Chief Executive Officer ,Response Evaluation Criteria ,Solid Tumors ,Bicycle Therapeutics ,Investors Media ,Cancer Research United Kingdom Centre ,Private Securities Litigation Reform Act ,Quarterly Report ,Capital Markets Investor Relations ,Bicycle ,Herapeutics ,Nnounces ,T5528 ,Hase ,Nose ,Escalation ,Results ,Patients ,Dvanced ,Olid ,Rumors ,